Boditech Med Inc.
Financials
Valuation Metrics
Boditech Med Inc.'s Market Cap is ₩2473B. At end of 2025 it was ₩2874B. Ranked #716 of 2,436 in KR market (top 29%), #306 of 1,649 on KOSDAQ (top 19%), #23 of 96 in Health Care Equipment & Services (top 24%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 247.34B KRW | KR#716/2,436 Sec#23/96 |
| Revenue | 165.84B KRW | KR#1,113/2,436 Sec#14/96 |
| Net Income | 26.12B KRW | KR#557/2,436 Sec#14/96 |
| Total Assets | 296.01B KRW | KR#1,027/2,436 Sec#23/96 |
| Net Assets | 255.10B KRW | KR#786/2,436 Sec#16/96 |
| Employees | 532 | KR#465/2,436 Sec#7/96 |
| Value | ||
| P/E | 9.47x | KR#672/2,436 Sec#16/96 |
| P/B | 0.97x | KR#1,464/2,436 Sec#37/96 |
| PEG | 0.31x | KR#596/2,436 Sec#23/96 |
| P/S | 1.49x | KR#1,656/2,436 Sec#41/96 |
| EV/EBITDA | 8.35x | KR#489/2,436 Sec#15/96 |
| FCF Yield | -4.42% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | 10.24% | KR#489/2,436 Sec#21/96 |
| ROA | 8.82% | KR#270/2,436 Sec#17/96 |
| Op. Margin | 16.68% | KR#223/2,436 Sec#19/96 |
| Revenue Growth | 9.58% | KR#941/2,436 Sec#44/96 |
| Earnings Growth | 30.85% | KR#688/2,436 Sec#28/96 |
| Financial Health | ||
| Debt Ratio | 116.04% | KR#560/2,436 Sec#26/96 |
| Total Debt | 23.53B KRW | KR#1,299/2,436 Sec#36/96 |
| FCF | -10.93B KRW | KR#1,741/2,436 Sec#65/96 |
| Cash | 39.74B KRW | KR#865/2,436 Sec#16/96 |
| Current Ratio | 5.55x | KR#255/2,436 Sec#17/96 |
| Net Debt/EBITDA | -0.59x | KR#563/2,436 Sec#22/96 |
| Dividend | ||
| Div. Yield | 1.33% | KR#1,055/2,436 Sec#32/96 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/96 |
| Performance | ||
| 1Y Return | -18.48% | KR#1,221/2,436 Sec#35/96 |
| 1M Return | 3.67% | KR#559/2,436 Sec#27/96 |
| From 52W High | -24.73% | KR#260/2,436 Sec#7/96 |
| 1Y MDD | -37.80% | KR#444/2,436 Sec#12/96 |
| Trading | ||
| Volume | 116,697 shares | KR#849/2,436 Sec#36/96 |
| Foreign Own. | 2.98% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | 1,118 KRW | KR#583/2,436 Sec#12/96 |
| BPS | 11,130 KRW | KR#879/2,436 Sec#16/96 |
Company Info
Boditech Med, established in 1998 as an in-vitro diagnostics specialist, operates production corporations in the US and China, expanding its diagnostics market. Leveraging lateral flow immunofluorescence technology, the company possesses over 100 types of disease diagnostic product lines and has diversified sales channels by establishing sales networks in over 130 countries worldwide. It has developed next-generation and automated immunoassay platforms, laying the groundwork for entry into advanced markets and large hospitals, and is aspiring to become a global diagnostics company through the development of high-value-added diagnostic cartridges. Its headquarters are in Chuncheon-si, Gangwon-do.